Get the Stockscreener App
3.80
17.65%
0.57
Quantum Biopharma Ltd stock is traded at $3.80, with a volume of 271.30K.
It is up +17.65% in the last 24 hours and up +8.88% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$3.23
Open:
$3.34
24h Volume:
271.30K
Relative Volume:
0.99
Market Cap:
$24.43M
Revenue:
-
Net Income/Loss:
$-31.97M
P/E Ratio:
-0.46
EPS:
-8.2612
Net Cash Flow:
$-5.66M
1W Performance:
+10.14%
1M Performance:
+8.88%
6M Performance:
+4.40%
1Y Performance:
-66.00%
1-Day Range:
$3.31
$3.95
1-Week Range:
$3.11
$4.08
52-Week Range:
$2.07
$14.85
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.80 | 22.37M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma Stock Surges as Lucid-MS Progress and Biotech Catalysts Fuel Bullish Momentum - kalkine.ca
Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Fresh Pressure as Biotech Risk and Funding Concerns Weigh on Sentiment - kalkine.ca
Quantum BioPharma reports Q2 results, FDA clears MS trial - Investing.com
Quantum BioPharma Reports Q2 2026 Results, Reduces Operating Expenses 53% and Secures FDA Clearance for Lucid-MS Phase 2 Trial - Quiver Quantitative
Quantum BioPharma Announces Q2 2026 Financials and FDA Approval for Lucid-MS Phase 2 Trial in Progressive MS - Kalkine Media
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial - marketscreener.com
Quantum BioPharma (QNTM) doubles liquidity and secures FDA clearance for Lucid-MS Phase 2 - Stock Titan
Quantum BioPharma Strengthens Equity and Liquidity in Q2 - GlobeNewswire
Quantum Biopharma (QNTM) narrows Q2 loss but leans on crypto and new debt - Stock Titan
Quantum BioPharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - Yahoo Finance
Quantum BioPharma (QNTM) ties August 10 press release into Form F-3 - Stock Titan
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - TradingView
FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 — QNTM Shares Slide Anyway - kalkine.ca
Quantum BioPharma Ltd. (CN:QNTM) Shares Decline as Clinical Development Risks and Biotech Market Volatility Pressure Investor Sentiment - kalkine.ca
QUANTUM BIOPHAR (QNTM) Eps Diluted (TTM) - Zacks Investment Research
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial - Currently.com
Quantum BioPharma Ltd. Stock Surges 7.52% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Quantum BioPharma (QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 - Yahoo Finance
Quantum Biopharma Ltd. Receives United States Fda Clearance to Proceed with Lucid-Ms Phase 2 Trial in Progressive Multiple Sclerosis - marketscreener.com
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2 - Barchart.com
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: - BNN Bloomberg
Quantum BioPharma (QNTM) Advances MS Treatment with FDA Approval Amid High Price-to-Sales Valuation - GuruFocus
FDA approves Quantum BioPharma IND for MS therapy phase 2 trial - Investing.com Australia
Quantum BioPharma Secures FDA IND Approval to Launch Lucid-MS® Phase 2 Trial for Progressive Multiple Sclerosis - Kalkine Media
Quantum Biopharma Ltd. R (0K91.MU) stock price, news, quote and history - Yahoo Finance UK
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis - marketscreener.com
Quantum BioPharma (QNTM) wins FDA IND clearance to start Lucid-MS Phase 2 in progressive MS - Stock Titan
Lucid-MS heads toward a double-blind Phase 2 trial for progressive MS - Stock Titan
Quantum BioPharma Stock Surges 8.64% as Drug Development Pipeline and Biotech Potential Attract Investor Interest - kalkine.ca
Quantum BioPharma Ltd (QNTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quantum BioPharma Ltd. (CN:QNTM) Extends Decline as Clinical Risk and Weak Sentiment Pressure Shares - kalkine.ca
Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Resul - Benzinga
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy - USA Today
Quantum Biopharma Ltd expected to post a loss of 42 cents a shareEarnings Preview - TradingView
QNTM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Quantum BioPharma Ltd (QNTM) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Quantum BioPharma settles CAD$123K debt by issuing shares to creditors - Pluang
Quantum BioPharma Ltd. Closes CAD$123,487.43 Debt Settlement Through Share Issuance - Quiver Quantitative
Quantum BioPharma Announces Closing of Debt Settlement - GlobeNewswire
Quantum BioPharma Stock Climbs 4.50%: Drug Development Progress and Biotechnology Innovation Strengthen Investor Confidence - kalkine.ca
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans - TradingView
Quantum BioPharma Ltd (QNTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans - Yahoo Finance
Quantum BioPharma Ltd (QNTM) Institutional Confidence - TradingKey
Quantum BioPharma Ltd (QNTM) Balance Sheet - TradingKey
5 Stocks To BUY HEAVY Before June 2026 Pentagone Ovnis (6uU0VmOjAy) - Mshale
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Revenue Breakdown – FWB:0K91 - TradingView
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):